title: Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial.
abstract: OBJECTIVE
  Our aim was to determine the efficacy and toxicity of paclitaxel in the treatment of refractory and platinum-resistant epithelial ovarian cancer.
  
  
  METHODS
  Eligibility required three prior failed chemotherapy regimens and documented platinum resistance. One hundred patients with advanced ovarian cancer received paclitaxel 135 mg/m2 over 24 hours every 21 days with optional granulocyte colony-stimulating factor support.
  
  
  RESULTS
  Paclitaxel was generally well tolerated. In four patients bowel perforation or fistula developed. After three cycles 34% of patients had stable disease and 25% of patients demonstrated a response, either partial or complete. After six cycles 24% of patients continued to respond. To date, six patients have achieved a complete response.
  
  
  CONCLUSIONS
  A 25% response rate in patients with refractory ovarian cancer was observed, which was durable to six cycles.
authors.affiliation: Department of Medicine, University of Washington Medical Center 98155.
authors.forename: V L
authors.initials: VL
authors.lastname: Seewaldt
authors.forename: B E
authors.initials: BE
authors.lastname: Greer
authors.forename: J M
authors.initials: JM
authors.lastname: Cain
authors.forename: D C
authors.initials: DC
authors.lastname: Figge
authors.forename: H K
authors.initials: HK
authors.lastname: Tamimi
authors.forename: W S
authors.initials: WS
authors.lastname: Brown
authors.forename: S A
authors.initials: SA
authors.lastname: Miller
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel